|1.63|| -0.01 / -0.61%|
Galena Biopharma, Inc. is a biotechnology company focused on discovering, developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care. Its development portfolio ranges from mid to late stage clinical assets which include program led by NeuVax. The company's commercial drugs include Abstral (fentanyl) Sublingual Tablets and Zuplenz (ondansetron) Oral Soluble Film. The company focuses on identifying and advancing therapeutic opportunities to improve cancer care from direct treatment of the disease to the reduction of its debilitating side effects. Galena Biopharma was founded by Craig Mello on April 3, 2006 and is headquartered in Portland, OR.
|Mark W. Schwartz||President, Chief Executive Officer & Director|
|Gavin S. Choy||Senior VP-Clinical Sciences & Operations|
|Ryan M. Dunlap||VP, Chief Financial & Accounting Officer|
|Patricia A. Murphy||Vice President-Regulatory & Compliance|
|Christopher S. Lento||Senior Vice President-Commercial Operations|